The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group
Abstract
Purpose: Adjuvant therapy for breast cancer can be associated with decreased bone mineral density (BMD) that may lead to skeletal morbidity. This study examined whether zoledronic acid can prevent bone loss associated with adjuvant endocrine therapy in premenopausal patients. Patients and Methods: This study is a randomized, open-label, phase III, four-arm trial comparing tamoxifen (20 mg/d orally) and goserelin (3.6 mg every 28 days subcutaneously) ± zoledronic acid (4 mg intravenously every 6 months) versus anastrozole (1 mg/d orally) and goserelin ± zoledronic acid for 3 years in premenopausal women with hormone-responsive breast cancer. In a BMD subprotocol at three trial centers, patients underwent serial BMD measurements at 0, 6, 12, 24, and 36 months. Results: Four hundred one patients were included in the BMD subprotocol. Endocrine treatment without zoledronic acid led to significant (P < .001) overall bone loss after 3 years of treatment (BMD, −14.4% after 36 months; mean T score reduction, −1.4). Overall bone loss was significantly more severe in patients receiving anastrozole/goserelin (BMD, −17.3%; mean T score reduction, −2.6) compared with patients receiving tamoxifen/goserelin (BMD, −11.6%; mean T score reduction, −1.1). In contrast, BMD remained stable in zoledronic acid–treated patients (P < .0001 compared with endocrine therapy alone). No interactions with age or other risk factors were noted. Conclusion: Endocrine therapy caused significant bone loss that increased with treatment duration in premenopausal women with breast cancer. Zoledronic acid 4 mg every 6 months effectively inhibited bone loss. Regular BMD measurements and initiation of concomitant bisphosphonate therapy on evidence of bone loss should be considered for patients undergoing endocrine therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
ASSESSMENT OF FRACTURE RISK AND ITS APPLICATION TO SCREENING FOR POSTMENOPAUSAL OSTEOPOROSIS
Alexeeva, L. P., Burkhardt, P., Christiansen, C., Cooper, C. C., Delmas, P. D., Johnell, O., Johnston, C. C., Kanis, J. A., Lips, P. T. A. M., Melton, L. J., et al. (1994) · Cited by 2,655
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures
Siris, E. S., Chen, Y.-T., Abbott, T. A., Barrett-Connor, E., Miller, P. D., Wehren, L. E., & Berger, M. L. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.10.1108 · Cited by 1,093
The ATAC (Arimidex, T. A. O. I. C. T. G. (2003) · Cancer · doi:10.1002/cncr.11745 · Cited by 861
SMITH, M. R., EASTHAM, J., GLEASON, D. M., SHASHA, D., TCHEKMEDYIAN, S., & ZINNER, N. (2003) · Journal of Urology · doi:10.1097/01.ju.0000063820.94994.95 · Cited by 650
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., & Senn, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3817 · Cited by 582
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2004) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000115858.45890.53 · Cited by 315
Cited by
Bisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
Gnant, M., Mlineritsch, B., Luschin-Ebengreuth, G., Kainberger, F., Kässmann, H., Piswanger-Sölkner, J. C., Seifert, M., Ploner, F., Menzel, C., Dubsky, P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70204-3 · Cited by 396
Self-citation
Metadata
- Authors
- Gnant, M. F. X., Mlineritsch, B., Luschin-Ebengreuth, G., Grampp, S., Kaessmann, H., Schmid, M., Menzel, C., Piswanger-Soelkner, J. C., Galid, A., Mittlboeck, M., Hausmaninger, H., & Jakesz, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-03-01
- Volume
- 25
- Issue
- 7
- Pages
- 820-828
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2143151890
- Cited by
- 331
- References
- 24
- FWCI
- 20.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group. https://app.cochat.ai/papers/10.1200/jco.2005.02.7102
- The paper
- Gnant, M. F. X., Mlineritsch, B., Luschin-Ebengreuth, G., Grampp, S., Kaessmann, H., Schmid, M., Menzel, C., Piswanger-Soelkner, J. C., Galid, A., Mittlboeck, M., Hausmaninger, H., & Jakesz, R. (2007). Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.02.7102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
